GPE
Pfizer Boosts Revenue Forecast by $1.5 Billion Amid Paxlovid Rebound, Despite Criticism from Starboard
Pfizer, revenue outlook, Paxlovid, Starboard, pharmaceuticals, COVID-19, financial performance
Novartis Invests $150M in Monte Rosa’s Molecular Glue Technology for Autoimmune Diseases
Novartis, Monte Rosa, Molecular Glue, Protein Degradation, Autoimmune Diseases, MRT-6160, VAV1-degrader, Biotech Collaboration
Intellia’s CRISPR Therapy NTLA-2002 Shows 81% Reduction in Hereditary Angioedema Attacks in Phase 2 Study
CRISPR therapy, Intellia Therapeutics, NTLA-2002, Hereditary Angioedema (HAE), Gene editing, Phase 2 study, Swelling attacks, Functional cure
Pfizer Secures FDA Approval to Expand RSV Vaccine Abrysvo for High-Risk Adults Aged 18-59
Pfizer, RSV vaccine, Abrysvo, FDA approval, high-risk adults, immunocompromised adults
HLTH24: Atropos Health Introduces AI-Powered Chat Co-Pilot for Rapid Real-World Evidence Generation
Atropos Health, HLTH24, Chat-Based AI Co-Pilot, Real-World Evidence, Generative AI, Healthcare Evidence Generation, GENEVA OS, ChatRWD
Novo Nordisk’s Alhemo Nears EU Approval: A Breakthrough in Haemophilia Treatment
Novo Nordisk, Alhemo, Haemophilia A and B, Inhibitors, European Medicines Agency (EMA), CHMP positive opinion, Subcutaneous prophylactic treatment, Concizumab
Baxter to Import 18,000 Tons of IV Fluids by Year-End Amid Ongoing Hurricane Recovery Efforts
Baxter International, IV fluid shortage, Hurricane Helene, North Carolina, importation plans, healthcare crisis
Eisai to Seek Reconsideration of TGA’s Initial Decision on Lecanemab for Alzheimer’s Disease in Australia
Lecanemab, Alzheimer’s disease, Therapeutic Goods Administration (TGA), Eisai, Biogen, reconsideration, Australia
Sanofi Workers Strike Over Consumer Health Unit Sale Amid Job Loss and Strategic Asset Concerns
Sanofi, strike, consumer health unit, sale, job losses, strategic assets, France, Doliprane, Opella, Clayton Dubilier & Rice
Eli Lilly Expands Global Footprint with £279 Million Investment in UK’s Biotech Sector
Eli Lilly, Gateway Labs, UK biotech, life sciences, Alzheimer’s treatment, donanemab, investment, healthcare innovation